HOUSTON--(BUSINESS WIRE)--PLx Pharma announced today the initiation of a clinical trial to assess the gastrointestinal (GI) safety of PL 2200. PL 2200 is a molecular complex of aspirin and phosphatidylcholine that is being developed as a GI safer immediate-release aspirin to address the well known upper GI toxicity of aspirin.
